Indolent Lymphoma

• CLINICAL_TRIALS trial_result · 2024-09-27
  Clinical Trial Update: Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma [Phase 1]

  A Phase 1 dose-de-escalation study of copanlisib combined with nivolumab and rituximab for relapsed/refractory indolent lymphoma was termina…

• CLINICAL_TRIALS trial_result · 2024-09-19
  Clinical Trial Update: 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation [Phase 2]

  Phase 2 trial evaluating Zydelig (idelalisib) as maintenance therapy after autologous stem cell transplantation in B-cell non-Hodgkin lympho…

• CLINICAL_TRIALS trial_result · 2024-07-31
  Clinical Trial Update: Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia [Phase 1]

  Phase 1 study assessing TG-1801 alone or with ublituximab in patients with CLL, SLL, and other B-cell lymphomas was terminated.

• CLINICAL_TRIALS trial_result · 2024-06-11
  Clinical Trial Update: Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies [Phase 1]

  Phase 1 study of STRO-001, an anti-CD74 antibody-drug conjugate, in advanced B-cell malignancies has been completed.

• CLINICAL_TRIALS trial_result · 2022-09-16
  Clinical Trial Update: Low-dose Radiotherapy in iNHL [Phase 2]

  A Phase 2 clinical trial update investigating low-dose radiotherapy for indolent lymphoma is reported, with unclear status and sponsor infor…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS trial_result · 2021-01-13
  Clinical Trial Update: Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell Lymphoma [Phase 1, Phase 2]

  A phase 1/2 trial investigated lenalidomide, ixazomib, and rituximab as front-line therapy for high-risk indolent B-cell lymphoma; the study…

• CLINICAL_TRIALS trial_result · 2019-10-22
  Clinical Trial Update: Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma [Phase 2]

  Phase 2 clinical trial of bortezomib, cladribine, and rituximab in advanced mantle cell lymphoma or indolent lymphoma has completed with res…

• CLINICAL_TRIALS trial_result · 2011-01-28
  Clinical Trial Update: Non-randomized Safety Study With Bortezomib/Rituximab in Relapsed/Refractory Indolent Lymphoma [Phase 2]

  This document reports the completion of a Phase 2 non-randomized safety study evaluating the combination of Bortezomib and Rituximab in rela…

• CLINICAL_TRIALS trial_result · 2008-06-02
  Clinical Trial Update: 11C-Acetate PET/CT Non-FDG-Avid Tumors

  This clinical trial update discusses the use of 11C-acetate PET/CT for imaging tumors that do not take up FDG. It covers several cancer type…